Knockdown of VE-cadherin led to a significant increase in sensitivity to cisplatin in vitro (IC50 12.29 versus 3.23 nM, for H446 parental versus H446 VE-cadherin KD, P<0.0001; Supplementary Fig. 7a,b), consistent with the reduced cisplatin uptake by tumours (Fig. 8) due to impaired drug perfusion rather than a cell intrinsic increase in cisplatin resistance. Here, CDH5 is linked to neoplasm.